



Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Apeparvovec Therapy

John W. Day¹ · Jerry R. Mendell^{2,3,4} · Eugenio Mercuri^{5,6} · Richard S. Finkel^{7,8} · Kevin A. Strauss^{9,10,11,12} · Aaron Kleyn¹³ · Sitra Tauscher-Wisniewski¹³ · Francis Fonyuy Tukov¹³ · Sandra P. Reyna¹³ · Deepa H. Chand^{13,14}

Published online: 23 December 2021
© The Author(s) 2021

Correction to: Drug Safety (2021) 44:1109–1119
<https://doi.org/10.1007/s40264-021-01107-6>

In the original publication of the article, footnote marker ‘b’ was incorrectly placed in rows 2 and 3 of Table 4. The correct Table 4 is published here.

Table 4 Hepatotoxicity adverse events and laboratory findings

Hepatotoxicity	START (N = 15)	STRIVE-EU (N = 33)	STRIVE-US (N = 22)	SPRINT (N = 30)	STRIVE-AP (N = 2)	Total (N = 102)
Reported AEs	4 (26.7%)	18 (54.5)	7 (31.8)	8 (26.7) ^a	0	37 (36.3)
Elevations in LFT results (not reported as AEs)	10 (66.7)	12 (36.4)	13 (59.1)	19 (63.3)	1	54 (52.9)
Postdosing elevations in LFT results	15 (100)	29 (87.9)	20 (90.9)	26 (86.7)	0	90 (90.0)
Elevations in LFT results at baseline (prior to dosing) ^b	9 (60.0)	22 (66.7)	5 (22.7)	20 (66.7)	0	56 (54.9)

AEs adverse events, LFTs liver function tests, ULN upper limit of normal

^aOne of these events did not have laboratory abnormalities that were reported

^bLFTs included analysis of aspartate aminotransferase, alanine aminotransferase, and bilirubin; all were < 2 × ULN

The original article can be found online at <https://doi.org/10.1007/s40264-021-01107-6>.

✉ John W. Day
jwday@stanford.edu

¹ Department of Neurology, Stanford University Medical Center, MC 5979, 213 Quarry Road, Palo Alto, CA 94304, USA

² Center for Gene Therapy, Nationwide Children’s Hospital, Columbus, OH, USA

³ Department of Pediatrics, Ohio State University, Columbus, OH, USA

⁴ Department of Neurology, Ohio State University, Columbus, OH, USA

⁵ Department of Paediatric Neurology and Nemo Clinical Centre, Catholic University, Rome, Italy

⁶ Centro Clinico Nemo, Fondazione Policlinico Gemelli IRCCS, Rome, Italy

⁷ Department of Pediatrics, Nemours Children’s Hospital, Orlando, FL, USA

⁸ Center for Experimental Neurotherapeutics, St. Jude’s Children’s Research Hospital, Memphis, TN, USA

⁹ Clinic for Special Children, Strasburg, PA, USA

¹⁰ Penn Medicine-Lancaster General Hospital, Lancaster, PA, USA

¹¹ Department of Pediatrics, University of Massachusetts School of Medicine, Worcester, MA, USA

¹² Department of Molecular, Cell & Cancer Biology, University of Massachusetts School of Medicine, Worcester, MA, USA

¹³ Novartis Gene Therapies, Inc., Bannockburn, IL, USA

¹⁴ Department of Pediatrics, Washington University School of Medicine and St. Louis Children’s Hospital, St. Louis, MO, USA

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.